CRL - Charles River Laboratories International, Inc.
| Previous Close | 133.72 |
| Open | 133.76 |
| Bid | 133.81 x 1300 |
| Ask | 134.45 x 800 |
| Day's Range | 132.86 - 134.26 |
| 52 Week Range | 102.96 - 149.07 |
| Volume | 30,888 |
| Avg. Volume | 378,779 |
| Market Cap | 6.542B |
| Beta (3Y Monthly) | 1.16 |
| PE Ratio (TTM) | 29.04 |
| EPS (TTM) | 4.62 |
| Earnings Date | May 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 149.31 |
- Insider Monkey•21 hours ago
Were Hedge Funds Right About Piling Into Charles River Laboratories International (CRL)?
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- Simply Wall St.•23 hours ago
Here's How P/E Ratios Can Help Us Understand Charles River Laboratories International, Inc. (NYSE:CRL)
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E ratio and reflect on what it tells us about the...
- Zacks•11 days ago
Top Ranked Growth Stocks to Buy for April 12th
Top Ranked Growth Stocks to Buy for April 12th
- Zacks•11 days ago
Teladoc's Partnership to Form Pediatric Telehealth Platform
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.
- Business Wire•12 days ago
Charles River Laboratories Schedules First-Quarter 2019 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (CRL) will release first-quarter 2019 financial results on Tuesday, May 7th, before the market opens. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
- Markit•14 days ago
See what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CRL are favorable with net inflows of $70.87 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•14 days ago
Charles River Laboratories and CHDI Foundation Extend Huntington’s Disease Collaboration
Behind every patient stands thousands of scientists and researchers collaborating to develop life-saving drugs. Jenne’s story highlights the importance of that work.
- Zacks•18 days ago
Charles River Laboratories (CRL) Is Up 2.99% in One Week: What You Should Know
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks•19 days ago
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
- Zacks•20 days ago
4 GARP Stocks for a Winning Portfolio
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
- Zacks•21 days ago
Top Ranked Growth Stocks to Buy for April 2nd
Top Ranked Growth Stocks to Buy for April 2nd
- Zacks•21 days ago
Charles River (CRL) Hits 52-Week High, Can the Run Continue?
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Business Wire•28 days ago
Charles River Laboratories Highlights Commitment to Oncology Research at 2019 AACR Annual Meeting
Researchers will highlight work in BRCA-deficient and rare pediatric cancers
- GlobeNewswire•29 days ago
Report: Developing Opportunities within Bristol-Myers Squibb, AutoNation, FirstEnergy, Charles River Laboratories International, Yum! Brands, and AGNC Investment — Future Expectations, Projections Moving into 2019
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Zacks•last month
Encouraging Near-Term Outlook for Medical Services Industry
Encouraging Near-Term Outlook for Medical Services Industry
- Simply Wall St.•last month
At US$141, Is It Time To Put Charles River Laboratories International, Inc. (NYSE:CRL) On Your Watch List?
Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price increase onRead More...
- TheStreet.com•2 months ago
Why Charles River Labs Is the Biotech Stock to Buy: Jim Cramer
Ready to diversify your portfolio but unfamiliar with the biotech space? Here's a stock pick from Jim Cramer.
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
- Business Wire•2 months ago
Charles River Laboratories to Present at Raymond James and Barclays Investor Conferences
Charles River Laboratories International, Inc. announced today that it will present at two upcoming investor conferences, including:
- Zacks•2 months ago
US Economy Had a Banner 2018: Top 5 Gainers
The U.S. GDP grew 2.9% in 2018, matching 2015 as the biggest increase since the 2007-2009 Great Recession.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CRL earnings conference call or presentation 13-Feb-19 1:30pm GMT
Q4 2018 Charles River Laboratories International Inc Earnings Call
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
